- Trial phase
- Approved
- Time to market
- Already approved and commercially available in the US (initial approval July 2020, full approval April 2026) and EU (EMA approval 2021).
- Why 3/10
- Tecartus is already approved and commercialized with no pending PDUFA date, pivotal readout, or other hard binary catalyst scheduled in the next ~12 months. It is a small and declining revenue contributor within Gilead's diversified portfolio, so impactScore is capped at 3-5 per the rubric for approved drugs with no imminent regulatory decision.
Tecartus has no upcoming binary catalyst; the next major Gilead cell-therapy catalyst is the anito-cel PDUFA date on December 23, 2026, for relapsed/refractory multiple myeloma. Watch for further Tecartus sales erosion in Q4 2026 earnings (late January/early February 2027) and any potential earlier-line trial data that could reverse the decline.
Price Chart
Executive Summary
Tecartus (brexucabtagene autoleucel) is a CD19-directed CAR T-cell therapy developed by Kite Pharma, a subsidiary of Gilead Sciences (NASDAQ: GILD. It was first approved by the FDA in July 2020 for relapsed/refractory mantle cell lymphoma (MCL) and received full FDA full approval in April 2026 based on confirmatory ZUMA-2 Cohort 3 data. It is also approved for relapsed/refractory B-cell ALL. However, sales are declining sharply: Q3 2026 sales fell 28% YoY to $60M, driven by intense competition from other CD19 CAR-T therapies. Tecartus is a small part of Gilead's $31B+ annual revenue and has no upcoming binary catalyst in the next 12 months, making it a neutral watch for investors.
How It Works
Tecartus is a personalized cell therapy (CAR-T) made from a patient's own immune cells. The patient's T cells are collected, genetically modified in a lab to recognize and attack cancer cells that carry a protein called CD19, and then infused back into the patient. The modified T cells act as a living drug, seeking out and destroying CD19-positive cancer cells.
Trial Status
Tecartus received full FDA approval for relapsed/refractory MCL in July 2020 under accelerated approval, converted to full approval in April 2026 based on ZUMA-2 Cohort 3 confirmatory data. It also received FDA approval for relapsed/refractory B-cell ALL in October 2021 based on the ZUMA-2 and ZUMA-3 studies. Long-term follow-up data from ZUMA-2 Cohort 3 was reported at ASH 2024 and in 2026 publications.
The Two-Sided Case
Upcoming Catalysts
- No upcoming PDUFA date or pivotal readout scheduled for Tecartus in the next 12 months.
- Q4 2026 earnings report (expected late January/early February 2027) will show whether Tecartus sales decline continues.
- Potential earlier-line MCL or ALL trial data presentations at medical conferences (ASH, ASCO) could provide upside if positive.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GILEAD SCIENCES, INC. 8-K GILD ·Originating report